The Pneumococcus, Prominent Microbiologists, Contributions and Cross-Connections

‘He who knows syphilis knows medicine’ goes the saying. In a similar way this adage could be applied to the Pneumococcus, aka Streptococcus pneumoniae, Diplococcus pneumoniae or Diplococcus lanceolatus by saying “He who knows S. pneumoniae knows microbiology”. Many ‘big names’ studied the organism.  Their work on the Pneumococcus led to Continue reading The Pneumococcus, Prominent Microbiologists, Contributions and Cross-Connections

Discontinued But Not Forgotten: HCV Drugs That Did Not Make It

I find it useful to look back and review drug candidates that were stopped in development.  In case of insufficient efficacy, i.e., not enough of a VL reduction or early viral rebound, everyone can sympathize with the decision to discontinue a drug. More importantly, we want to learn about the Continue reading Discontinued But Not Forgotten: HCV Drugs That Did Not Make It

Commenting on Comments:  The Ceftaroline Trial Program in CABP

The ceftaroline (Teflaro®) program was executed at a time when FDA was debating a new CABP Guidance with new outcome measures: no longer was the time-honored TOC assessment acceptable, instead improvement on Day 3-5 was to become the new primary endpoint.  FDA made other significant changes to the old 1998 Continue reading Commenting on Comments:  The Ceftaroline Trial Program in CABP